Crossmark

The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies

Crossref DOI link: https://doi.org/10.1186/s12917-019-1811-2

Published Online: 2019-02-26

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Meier, A.

de Laat, M.

Reiche, D.

Fitzgerald, D.

Sillence, M. http://orcid.org/0000-0003-2837-5456
Funding

Funding for this research was provided by:

Boehringer Ingelheim (na)
License Information

Text and Data Mining valid from 2019-02-26
More Information

Article History

Received: 22 October 2018

Accepted: 19 February 2019

First Online: 26 February 2019

Ethics approval

: This study was approved by the Animal Care and Ethics Committees of Queensland University of Technology (1500000204) and The University of Queensland (QUT/SVS/470/14). All procedures were conducted in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes (NHMRC, 8th edition, 2013). All animals used in the study were owned by Queensland University of Technology and were used with the consent of the University.

: Not applicable.

: DR is an employee of the company that funded this research: Boehringer-Ingelheim.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.